Market Place
Sourcing Support
Gilead to Present Livdelzi and Bulevirtide Efficacy Data
23 Oct 2025 //
BUSINESSWIRE
80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
21 Oct 2025 //
BUSINESSWIRE
Gilead`s Trodelvy Cuts Breast Cancer Risk by 38% in Trial
20 Oct 2025 //
REUTERS
Kite Puts $1.64B On The Line For Pregene`s In Vivo Car-Ts
20 Oct 2025 //
FIERCE BIOTECH
Gilead To Present Latest Virology Data At IDWEEK 2025
19 Oct 2025 //
BUSINESSWIRE
ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
19 Oct 2025 //
FIERCE PHARMA
GSK Tout Study Showing Tolerability Edge for Its Long-Acting PrEP
15 Oct 2025 //
FIERCE PHARMA
Gilead, Kite To Revolutionize Cancer Care With ESMO 2025 Data
14 Oct 2025 //
INDPHARMAPOST
Gilead, Kite Showcase Cancer Care Transformation At ESMO 2025
13 Oct 2025 //
BUSINESSWIRE
Gilead, Arcus Keep TIGIT Dream Alive With 27-Month OS Data
13 Oct 2025 //
FIERCE BIOTECH
Gilead Sciences To Report Q3 2025 Financial Results On October 30
09 Oct 2025 //
BUSINESSWIRE
Gilead Inks Biktarvy Settlements With 3 Generic Drug Makers
07 Oct 2025 //
FIERCE PHARMA
Hanmi`s Oral Delivery Platform Compound Licensed To Gilead
29 Sep 2025 //
PR NEWSWIRE
Gilead Pumps Up Virology Pipeline With Drug Transporter Deal
29 Sep 2025 //
PR NEWSWIRE
TWN Urges Universal $40/year Access To Generic Lenacapavir
26 Sep 2025 //
PHARMABIZ
Gilead Invests $6.5M In STEM Education In San Francisco Bay
25 Sep 2025 //
CONTRACTPHARM
Lupin Gets Tentative FDA Nod For Biktarvy Tablets
25 Sep 2025 //
EXPRESSPHARMA
CDC Strongly Recommends Gilead`s HIV PrEP Yeztugo
19 Sep 2025 //
FIERCE PHARMA
Study: One-Third of Trial Data May Be Unnecessary
19 Sep 2025 //
FIERCE BIOTECH
Marengo Therapeutics Expands STARt-002 Trial to Phase 2
18 Sep 2025 //
PR NEWSWIRE
Fangzhou Wins Gilead ‘Award of Excellence’ for AI Management
17 Sep 2025 //
GLOBENEWSWIRE
Gilead Beats Whistleblower Lawsuit over Hepatitis C drugs
15 Sep 2025 //
REUTERS
Gilead Launches New Primary Biliary Cholangitis Campaign
10 Sep 2025 //
FIERCE PHARMA
Gilead Sciences Partners with Veeva Vault CRM
10 Sep 2025 //
PRESS RELEASE
Vyome Holdings Bolsters Team for Pivotal Trial Studies
09 Sep 2025 //
PHARMAWEB
Xilio Starts Ph 2 XTX301 Trial, Hits $17.5M Gilead Milestone
09 Sep 2025 //
GLOBENEWSWIRE
IDEAYA Reveals Ph 1/2 Trial Data of IDE397 & Trodelvy in Cancer
08 Sep 2025 //
PR NEWSWIRE
US Plans to Bring Gilead HIV Drug to Market
05 Sep 2025 //
REUTERS
Gilead Urges HIV Patients to `Choose U` in Campaign
04 Sep 2025 //
FIERCE PHARMA
Gilead Starts Construction on Development & Manufacturing Center
04 Sep 2025 //
CONTRACTPHARMA
Gilead Partners PEPFAR for Biannual Lenacapavir Supply
04 Sep 2025 //
BUSINESSWIRE
Gilead breaks ground on production hub as part of $32B US outlay
04 Sep 2025 //
FIERCE PHARMA
Gilead Breaks Ground on Production Hub as Part of $32B US Outlay
03 Sep 2025 //
FIERCE PHARMA
Gilead`s Kite Erodes $2.3B Shoreline Cell Therapy Deal
03 Sep 2025 //
FIERCE BIOTECH
EU approves Gilead`s new injection for preventing HIV
27 Aug 2025 //
REUTERS
Gilead Sciences`s Yeytuo Receives Approval in Europe
25 Aug 2025 //
EMA
CVS Denies Coverage for Gilead`s Biannual PrEP Drug Yeztugo
21 Aug 2025 //
FIERCE PHARMA
Gilead Sciences to Attend Future Investor Conferences
20 Aug 2025 //
BUSINESSWIRE
Gilead Reports 7% Sales Decline for CAR-T`s Yescarta, Tecartus
12 Aug 2025 //
FIERCE PHARMA
Gilead Sciences`s Hepcludex Receives Approval in Canada
08 Aug 2025 //
FDA
Gilead Ends Last MASH Program, Drops 2 Cancer Assets
08 Aug 2025 //
FIERCE BIOTECH
Gilead`s CAR-Ts Yescarta, Tecartus Sales Drop by 7%
08 Aug 2025 //
FIERCE PHARMA
Gilead Confident in PrEP Despite Task Force Uncertainty
08 Aug 2025 //
BIOSPACE
Gilead Sciences Reveals Q2 2025 Financial Results
07 Aug 2025 //
BUSINESSWIRE
AbbVie, Gilead, GSK Support Annual Hepatitis Elimination Drive
29 Jul 2025 //
FIERCE PHARMA
Lilly`s Kisunla, Gilead`s Pr Ep Drug Yeytuo Gain CHMP Nods
25 Jul 2025 //
FIERCE PHARMA
Gilead Gets CHMP Nod for Lenacapavir HIV Prevention
25 Jul 2025 //
BUSINESSWIRE
EU Backs Gilead`s Twice-Yearly Injection for HIV Prevention
25 Jul 2025 //
REUTERS
Gilead Sciences to Release Second Quarter 2025 Financial Results
24 Jul 2025 //
BUSINESSWIRE
Gilead`s Ongoing Commitment to End HIV Epidemic
23 Jul 2025 //
ACCESSWIRE
Hookipa, Having Sold Off Vaccines to Gilead, Opts to Wind Down
21 Jul 2025 //
FIERCE BIOTECH
WHO recommends Gilead`s twice-yearly injection for HIV prevention
15 Jul 2025 //
REUTERS
Gilead Unveils Lenacapavir Data for HIV Prevention at IAS 2025
14 Jul 2025 //
BUSINESSWIRE
Gilead Enlists Global Fund in Access Campaign for New PrEp Med
10 Jul 2025 //
PRESS RELEASE
Gilead, Global Fund Finalize Deal for Lenacapavir HIV Prevention
09 Jul 2025 //
BUSINESSWIRE
Scotus Ruling Paves Smooth Launch Path for Gilead`s Yeztugo
02 Jul 2025 //
FIERCE PHARMA
Gilead Blames Low Infection Rates for Ending 2 RSV Trials
28 Jun 2025 //
FIERCE BIOTECH
Gilead Shares Rise After Top Court Ruling on Preventive Coverage
28 Jun 2025 //
REUTERS
Gilead Signs up to $750 Million Cancer Drug Deal with Kymera
27 Jun 2025 //
PRESS RELEASE
Gilead Shares Kim’s Story of Growing Up With HIV in 1980s
24 Jun 2025 //
ACCESSWIRE
